Clavanin bacterial sepsis control using a novel methacrylate nanocarrier

Amanda CM Saúde,1 Alicia S Ombredane,1 Osmar N Silva,1 João ARG Barbosa,1,2 Susana E Moreno,3 Ana Claudia Guerra Araujo,4 Rosana Falcão,4 Luciano P Silva,4 Simoni C Dias,1 Octávio L Franco1,3 1Programa de Pós Graduação em...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Saúde ACM, Ombredane AS, Silva ON, Barbosa JARG, Moreno SE, Guerra Araujo AC, Falcão R, Silva LP, Dias SC, Franco OL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/54453fe401154f86bacaaa48505fc5f3
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:54453fe401154f86bacaaa48505fc5f3
record_format	dspace
spelling	oai:doaj.org-article:54453fe401154f86bacaaa48505fc5f32021-12-02T02:32:06ZClavanin bacterial sepsis control using a novel methacrylate nanocarrier1178-2013https://doaj.org/article/54453fe401154f86bacaaa48505fc5f32014-10-01T00:00:00Zhttp://www.dovepress.com/clavanin-bacterial-sepsis-control-using-a-novel-methacrylate-nanocarri-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Amanda CM Saúde,1 Alicia S Ombredane,1 Osmar N Silva,1 João ARG Barbosa,1,2 Susana E Moreno,3 Ana Claudia Guerra Araujo,4 Rosana Falcão,4 Luciano P Silva,4 Simoni C Dias,1 Octávio L Franco1,3 1Programa de Pós Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília, Brasília, FD, Brazil; 2Laboratório de Biofísica-Departamento de Biologia Celular-IB, Universidade de Brasília – UNB, DF, Brazil; 3Universidade Católica Dom Bosco – UCDB, Campo Grande, MS, Brazil; 4Empresa Brasileira de Pesquisa Agropecuária – EMBRAPA – Recursos Genéticos e Biotecnologia, Brasília, DF, Brazil Abstract: Controlling human pathogenic bacteria is a worldwide problem due to increasing bacterial resistance. This has prompted a number of studies investigating peptides isolated from marine animals as a possible alternative for control of human pathogen infections. Clavanins are antimicrobial peptides isolated from the marine tunicate Styela clava, showing 23 amino acid residues in length, cationic properties, and also high bactericidal activity. In spite of clear benefits from the use of peptides, currently 95% of peptide properties have limited pharmaceutical applicability, such as low solubility and short half-life in the circulatory system. Here, nanobiotechnology was used to encapsulate clavanin A in order to develop nanoantibiotics against bacterial sepsis. Clavanin was nanostructured using EUDRAGIT® L 100-55 and RS 30 D solution (3:1 w:w). Atomic force, scanning electron microscopy and dynamic light scattering showed nanoparticles ranging from 120 to 372 nm in diameter, with a zeta potential of -7.16 mV and a polydispersity index of 0.123. Encapsulation rate of 98% was assessed by reversed-phase chromatography. In vitro bioassays showed that the nanostructured clavanin was partially able to control development of Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Furthermore, nanostructures did not show hemolytic activity. In vivo sepsis bioassays were performed using C57BL6 mice strain inoculated with a polymicrobial suspension. Assays led to 100% survival rate under sub-lethal sepsis assays and 40% under lethal sepsis assays in the presence of nanoformulated clavanin A until the seventh day of the experiment. Data here reported indicated that nanostructured clavanin A form shows improved antimicrobial activity and has the potential to be used to treat polymicrobial infections. Keywords: peptides, antimicrobial, nanoparticles, nanobiotechnologySaúde ACMOmbredane ASSilva ONBarbosa JARGMoreno SEGuerra Araujo ACFalcão RSilva LPDias SCFranco OLDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 5055-5069 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Saúde ACM Ombredane AS Silva ON Barbosa JARG Moreno SE Guerra Araujo AC Falcão R Silva LP Dias SC Franco OL Clavanin bacterial sepsis control using a novel methacrylate nanocarrier
description	Amanda CM Saúde,1 Alicia S Ombredane,1 Osmar N Silva,1 João ARG Barbosa,1,2 Susana E Moreno,3 Ana Claudia Guerra Araujo,4 Rosana Falcão,4 Luciano P Silva,4 Simoni C Dias,1 Octávio L Franco1,3 1Programa de Pós Graduação em Ciências Genômicas e Biotecnologia, Centro de Análises Proteômicas e Bioquímicas, Universidade Católica de Brasília, Brasília, FD, Brazil; 2Laboratório de Biofísica-Departamento de Biologia Celular-IB, Universidade de Brasília – UNB, DF, Brazil; 3Universidade Católica Dom Bosco – UCDB, Campo Grande, MS, Brazil; 4Empresa Brasileira de Pesquisa Agropecuária – EMBRAPA – Recursos Genéticos e Biotecnologia, Brasília, DF, Brazil Abstract: Controlling human pathogenic bacteria is a worldwide problem due to increasing bacterial resistance. This has prompted a number of studies investigating peptides isolated from marine animals as a possible alternative for control of human pathogen infections. Clavanins are antimicrobial peptides isolated from the marine tunicate Styela clava, showing 23 amino acid residues in length, cationic properties, and also high bactericidal activity. In spite of clear benefits from the use of peptides, currently 95% of peptide properties have limited pharmaceutical applicability, such as low solubility and short half-life in the circulatory system. Here, nanobiotechnology was used to encapsulate clavanin A in order to develop nanoantibiotics against bacterial sepsis. Clavanin was nanostructured using EUDRAGIT® L 100-55 and RS 30 D solution (3:1 w:w). Atomic force, scanning electron microscopy and dynamic light scattering showed nanoparticles ranging from 120 to 372 nm in diameter, with a zeta potential of -7.16 mV and a polydispersity index of 0.123. Encapsulation rate of 98% was assessed by reversed-phase chromatography. In vitro bioassays showed that the nanostructured clavanin was partially able to control development of Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Furthermore, nanostructures did not show hemolytic activity. In vivo sepsis bioassays were performed using C57BL6 mice strain inoculated with a polymicrobial suspension. Assays led to 100% survival rate under sub-lethal sepsis assays and 40% under lethal sepsis assays in the presence of nanoformulated clavanin A until the seventh day of the experiment. Data here reported indicated that nanostructured clavanin A form shows improved antimicrobial activity and has the potential to be used to treat polymicrobial infections. Keywords: peptides, antimicrobial, nanoparticles, nanobiotechnology
format	article
author	Saúde ACM Ombredane AS Silva ON Barbosa JARG Moreno SE Guerra Araujo AC Falcão R Silva LP Dias SC Franco OL
author_facet	Saúde ACM Ombredane AS Silva ON Barbosa JARG Moreno SE Guerra Araujo AC Falcão R Silva LP Dias SC Franco OL
author_sort	Saúde ACM
title	Clavanin bacterial sepsis control using a novel methacrylate nanocarrier
title_short	Clavanin bacterial sepsis control using a novel methacrylate nanocarrier
title_full	Clavanin bacterial sepsis control using a novel methacrylate nanocarrier
title_fullStr	Clavanin bacterial sepsis control using a novel methacrylate nanocarrier
title_full_unstemmed	Clavanin bacterial sepsis control using a novel methacrylate nanocarrier
title_sort	clavanin bacterial sepsis control using a novel methacrylate nanocarrier
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/54453fe401154f86bacaaa48505fc5f3
work_keys_str_mv	AT saudeacm clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT ombredaneas clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT silvaon clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT barbosajarg clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT morenose clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT guerraaraujoac clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT falcaor clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT silvalp clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT diassc clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier AT francool clavaninbacterialsepsiscontrolusinganovelmethacrylatenanocarrier
_version_	1718402408130805760

Clavanin bacterial sepsis control using a novel methacrylate nanocarrier

Ejemplares similares